Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Metastatic or Recurrent Thymic Carcinoma
NCT02623127Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Oct 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in thymic carcinoma (TC), sponsored by Seoul National University Hospital. Started Oct 2015; status: completed.
02
Drugs
sunitinib
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT02623127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623127.